tbuckley/cabot-search huggingface dataset:
THE CORRECTION OF FECAL INCONTINENCE BY SUBMUCOUS INJECTION OF PARAFFIN.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Commentaire de travail de G. R. Linke et al., pp. 571
Journal: Endoscopy (2010)

G. R. Linke, I. Tarantino, R. Hoetzel, R. Warschkow, J. Lange, R. Lachat, A. Zerz. Cholecystectomie par voie transvaginale par NOTES hybride rigide: évaluation en pratique de routine
Pneumoperitoneum for ventral hernia repair: anesthesia complication
Authors: W. C. Johnson
Journal: JAMA (1971)

<h3>To the Editor.—</h3> In the past three years, I have been using progressive pneumoperitoneum in the preoperative preparation of patients with large abdominal wall defects. This technique was introduced in Buenos Aires in 1940 by Ivan G. Moreno<sup>1</sup>and after Koontz's initial report<sup>2</sup>in this country in 1954 there have been reports by several authors.<sup>3-5</sup>A recent complication during induction with nitrous oxide anesthesia has prompted me to report the potential hazards of anesthesia in patients with pneumoperitoneum. <h3>Report of a Case.—</h3> A 52-year-old woman with recurrent ventral hernia had previously had seven abdominal operations including two hernia repairs. She had smoked two packages of cigarettes a day for the past 32 years and had one-flight dyspnea on exertion. Physical examination revealed a height of 5 ft 4 in; weight, 150 lb; blood pressure, 200/160 mm Hg; clear lungs; multiplesurgical scars on the abdomen with
<i>ERJ</i>Podcast August 2016: management of chronic thromboembolic pulmonary hypertension
Journal: European Respiratory Journal (2016)

Editorials /Complex lung function in severe asthma: seeing is believing page 294 / Primary ciliary dyskinesia: the patients grow up page 297 Originals /Insulin resistance modifies the association between obesity and current asthma in adults page 403 / Risk factors for short-term outcomes after thoracoscopic lobectomy for lung cancer page 495 Review /Development, roll-out, and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt, and how can we do better?page 516 / Quality of life in patients with chronic thromboembolic pulmonary hypertension page 526 Back to Basics /Age-driven developmental drift in the pathogenesis of idiopathic pulmonary fibrosis page 538
RESPONSE: Re: Limits of Predictive Models Using Microarray Data for Breast Cancer Clinical Treatment Outcome
Authors: James F. Reid, Lara Lusa, Loris De Cecco, Danila Coradini, Silvia Veneroni, Maria Grazia Daidone, Manuela Gariboldi, Marco A. Pierotti
Journal: JNCI Journal of the National Cancer Institute (2005)
Error in Byline
Journal: JAMA Network Open (2019)

Eyal Cohen, MD, MSc; Erzsébet Horváth-Puhó, MSc, PhD; Joel G. Ray, MD, MSc; Lars Pedersen, PhD; Vera Ehrenstein, MPH, DSc; Nancy Adler, PhD; Simone Vigod, MD, MSc; Arnold Milstein, MD; Henrik Toft Sørensen, MD, DMSc, PhD
CARE OF THE INSANE AND THE EPILEPTIC ON COLONY FARMS.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 2100: Resistance of gastric carcinoma cells towards c-met inhibition is mediated by compensatory HER3 upregulation involving SATB1 and PKC
Authors: Robert Jenke, Thomas Büch, Miriam Rein, Stefanie Müller, Florian Lordick, Achim M. Aigner
Journal: Cancer Research (2019)

Abstract Introduction: In patients with gastric cancer expressing high levels of c-met, inhibitors of the receptor tyrosine kinase (RTK) c-met are explored as targeted therapeutics. Unfortunately, clinical trials have failed to improve survival so far. This might be due to compensatory stimulation of other oncogenic RTKs. Here, we highlight the role of HER3 upregulation and its specific stimulation as resistance mechanism. On the mechanistic side, we demonstrate the genome regulator special AT-rich sequence-binding protein-1 (SATB1) as a critical mediator of this HER3 upregulation, with further manipulation being executed by contrary roles of Protein kinase C (PKC) and Phosphatidylinositol 3-kinase (PI3K). Methods: We used gastric cancer cell lines with a c-met amplification and evaluated the impact of pharmacological or siRNA-mediated c-met inhibition on cellular proliferation and survival. Moreover, we analyzed the expression of HER family receptors after inhibitor treatment. Furthermore, we used transient knockdown of SATB1 as well as inhibitors of PKC and PI3K to gain insight into signaling mechanisms. Results: The use of c-met kinase inhibitors or RNAi-induced downregulation of c-met led to a complete disruption of cellular proliferation. Without addition of c-met inhibitors, the investigated gastric cancer cells expressed HER1, HER2, and HER3 receptors, but no HER3 ligands. After pretreatment with c-met inhibitors, HER3 expression was markedly upregulated. Treatment of gastric cancer cells with the HER3 ligand beta-heregulin, usually secreted by cancer associated fibroblasts, partially reversed the anti-proliferative effects of c-met inhibitors. The induction of HER3 was reduced after pretreating cells with SATB1 siRNA. SATB1 is a known regulator of HER receptor expression in other tumor entities. The regulatory functions of SATB1 can be further modulated by phosphorylation via PKC or PI3K. Therefore, we investigated the effect of PKC and PI3K inhibition on HER3 induction. Of note, PKC inhibition markedly reduced HER3 upregulation, whereas PI3K inhibitors even increased HER3 levels. Conclusions: PKC and SATB1 are involved in the compensatory upregulation of HER3 upon c-met inhibition. Since this represents a critical resistance factor, interference with PKC and SATB1 signaling is a potential avenue to prevent resistance towards c-met inhibitors in gastric cancer. Citation Format: Robert Jenke, Thomas Büch, Miriam Rein, Stefanie Müller, Florian Lordick, Achim M. Aigner. Resistance of gastric carcinoma cells towards c-met inhibition is mediated by compensatory HER3 upregulation involving SATB1 and PKC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2100.
PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations
Authors: S.K. Sandhu, M. Hussain, J. Mateo, K. Fizazi, F. Saad, N. Shore, K. Chi, O. Sartor, N. Agarwal, D. Olmos, A. Thiery-Vuillemin, P. Twardowski, N. Mehra, C. Goessl, J. Kang, J. Burgents, W. Wu, A. Kohlmann, C. Adelman, J. de Bono
Journal: Annals of Oncology (2019)
FURTHER STATISTICAL STUDIES IN THE SPREAD OF MALIGNANT TUMORS.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Primary Biliary Cirrhosis
Authors: Marshall M. Kaplan
Journal: New England Journal of Medicine (1996)

Primary biliary cirrhosis is a chronic, progressive cholestatic liver disease of unknown cause that usually affects middle-aged women and eventually leads to liver failure and the need for liver transplantation. It is diagnosed more frequently now than it was a decade ago because of its greater recognition by physicians and the widespread use of automated blood testing and the antimitochondrial-antibody test, which is relatively specific for the disease.1 Important advances have been made in our understanding of the natural history, pathogenesis, and treatment of primary biliary cirrhosis since the subject was last reviewed in the Journal.2 Little has changed . . .
Which outcomes are reported in cellulitis trials? Results of a review of outcomes included in cellulitis trials and a patient priority setting survey
Authors: E. Smith, M. Patel, K. S. Thomas
Journal: British Journal of Dermatology (2018)

Cellulitis is a potentially serious bacterial infection of the skin tissue, usually occurring on the lower leg. In addition to short‐term signs and symptoms, the disease can have a significant long‐term impact on a patient's physical and mental health. Cellulitis also poses a significant burden to health services; for example, from 2014 to 2015 in England, 114,190 patients were treated in hospital for cellulitis with a median length hospital stay of 6 days. It has been recognised that many outcomes in clinical trials (meaning the results that the trial is looking for) vary from trial to trial, making it hard to compare results of different trials. For this reason, development of core outcome sets (COS) for trials would be useful. A COS is an agreed set of outcomes that should be measured and reported, as a minimum, in all clinical trials in a specific area of healthcare. The initial stage in developing a core outcome set is to identify what outcomes are available, and to establish which are most important and relevant for healthcare users. The purpose of this review, from the U.K., was to describe all the outcome measures reported in a type of trial called randomised control trials (RCTs) on the treatment and prevention of cellulitis. 48 trials were included in the final analysis, and each one had between one and eight outcome measures. The secondary aim of this study was to identify outcome themes from patient and healthcare professionals’ feedback from a cellulitis priority setting partnership (PSP). Priority Setting Partnerships help to bring patients, carers and clinicians together to identify and prioritise for research the treatment uncertainties which they agree are the most important. Prevention of recurrence was the most frequently stated outcome theme of importance from both patients and healthcare professionals. “Treatment‐focused” outcomes such as length of antibiotic therapy were also key priorities for healthcare professionals, while assessment of clinical features (redness, swelling and pain most commonly) were the next most important outcomes for patients. Surprisingly, only 2% of all outcome themes focused on quality of life and treatment satisfaction. The authors conclude that outcome measures for cellulitis should not only be consistent, to allow clinical trials to be adequately compared, but should be reflective of the real impact on patients’ day to day lives.
Arterial Disease
Authors: S. L. Wilens
Journal: JAMA (1965)

The late Simeon Burt Wolbach, one of the last of the truly great American pathologists, used to lament what he called the "vagaries" of arteriosclerosis. Mitchell and Schwartz, the authors of this fine new book on the subject, have removed most of the cause for this complaint. In 293 well-charted autopsies, they have explored the distribution of arteriosclerotic lesions throughout the arterial tree, plaque by plaque, in minute detail. Anyone desiring to find out how often a person with severe lesions in the right iliac artery also has similar changes in the left carotid need but consult their numerous charts and tables. It is indeed a far cry from 1927 when the first edition of Cecil's<i>Textbook of Medicine</i>covered the entire subject of myocardial infarction in less than a page. Even Herophilus, the reputed originator of the purposeful autopsy, would have been impressed by Mitchell and Schwartz's accomplishment. Habitual
CALCIUM AND FAT UTILIZATION IN INFANCY
Journal: JAMA (1918)

The ardent controversy as to the mode of absorption of fats from the alimentary tract has been settled. Although it would be difficult to demonstrate that no portion of ingested fat passes unaltered through the intestinal epithelium, there is no ground for believing in the older theory of absorption, which postulates the transit of the fat in emulsified form. On the contrary, there is reason to conclude that fats are chemically split in the gastro-intestinal canal into fatty acids and glycerol. The fatty acids react readily with bases to form soaps. The alkali soaps of sodium and potassium are somewhat soluble, whereas those of calcium and magnesium tend to be insoluble. Consequently, soaps of calcium are not infrequently found in the stools, particularly in the case of infants. These are familiar facts of elementary physiologic chemistry. The deductions drawn from them have not always been as logical as the facts
Analysis of Hydroxylated Metabolites of PCBs (OH-PCBs) and Other Chlorinated Phenolic Compounds in Whole Blood from Canadian Inuit
Authors: Courtney D. Sandau, Pierre Ayotte, Eric Dewailly, Jason Duffe, Ross J. Norstrom
Journal: Environmental Health Perspectives (2000)

In this study, we identified the main hydroxylated polychlorinated biphenyls (OH-PCBs) and other chlorinated phenolic compounds and we determined their relative concentrations in whole blood from 13 male and 17 female Inuit from northern Quebec, Canada, and from a pooled whole blood sample from southern Quebec. We also determined concentrations of polychlorinated biphenyls (PCBs). Total OH-PCB concentrations were variable among the Inuit samples, ranging over 2 orders of magnitude (0.117-11.6 ng/g whole blood wet weight). These concentrations were equal to and up to 70 times those found for the southern Quebec pooled whole blood sample. Geometric mean concentrations of total OH-PCBs were 1.73 and 1.01 ng/g whole blood for Inuit men and women, respectively, and 0.161 ng/g whole blood for the southern population pool. There are limited data available for comparison, but the levels of OH-PCBs in Inuit are higher than those previously reported in the literature for other populations. There was a significant correlation (p < 0.005) between OH-PCBs and PCBs (r = 0.84) and both correlated significantly (p < 0.005) with age (r = 0.68 and 0.78, respectively). The ratio of OH-PCBs to PCBs was lower in Inuit (0.11) than in the southern Quebec pool (0.33). There is no apparent explanation for the difference. There was considerable variability in the congener pattern of the identified OH-PCBs. The main metabolite, 4-OH-CB109 (4-OH-2,3,3',4', 5-pentachlorobiphenyl), constituted 12-62% of the total OH-PCBs in the samples. Pentachlorophenol (PCP) was the dominant phenolic compound in blood, constituting 46% (geometric mean) of the total quantitated chlorinated phenolic compounds. PCP concentrations in Inuit blood ranged from 0.558 to 7.77 ng/g on a wet weight basis. All but two Inuit samples had lower concentrations than the southern Quebec pool (6.29 ng/g). The possible role of OH-PCBs in mediating PCB-induced adverse effects needs to be investigated further.
Prevalence of Disabilities and Associated Health Conditions Among Adults—United States, 1999
Journal: JAMA (2001)

In the United States, the number of persons reporting disabling conditions increased from 49 million during 1991-1992 to 54 million during 1994-1995. During 1996, direct medical costs for persons with disability were $260 billion. Surveillance of disability prevalence and associated health conditions is useful in setting policy, anticipating the service needs of health systems, assisting state programs, directing health promotion and disease prevention efforts, and monitoring national health objectives. The U.S. Bureau of the Census and CDC analyzed data from the Survey of Income and Program Participation (SIPP) to determine national prevalence estimates of adults with disabilities and associated health conditions. This report summarizes findings of that analysis, which indicate that disability continues to be an important public health problem, even among working adults, and arthritis or rheumatism, back or spine problems, and heart trouble/hardening of the arteries remain the leading causes. Better health promotion and disease prevention may reduce the prevalence of disability-associated health conditions.
Phase II study of CC-4047 in patients with metastatic hormone-refractory prostate cancer (HRPCa)
Authors: B. Sison, T. Bond, R. J. Amato, D. Crawford, F. Crighton
Journal: Journal of Clinical Oncology (2004)

4701 Background: Thalidomide is a potentially effective therapy for patients with metastatic HRPC. CC-4047 is a thalidomide analog with a variety of immunomodulatory and anti-angiogenesis properties similar to thalidomide. This study investigates whether single agent CC-4047 can induce PSA responses and increase time to progression in HRPC. Eligibility included histologically confirmed adenocarcinoma of the prostate, 2 consecutive rises in prostate-specific antigen (PSA) consisting of an absolute change of at least 1 ng/ml separated by at least 28 days, with or without radiographic evidence of disease, castrate levels of serum testosterone (<50 ug/l), failure to antiandrogen withdrawal, ≤ 1 prior chemotherapy regimen, ECOG performance status of ≤ 1, life expectancy ≥ 3 months, and normal organ/marrow function. Methods: CC-4047 was administered orally in doses of 1 mg/day with no interruption. Patients are followed every 4 weeks with reevaluation at week 12. 22 patients have been enrolled to date. Patient characteristics; median age 69 years (range 58–82). 14 patients with bone involvementonly. 4 patients with bone and nodal involvement. 4 patients with nodal or visceral tumor without bone involvement. Results: Of the 22 patients, 9 patients have completed 12 weeks of therapy. 13 patients remain on study. PSA decreased in 6 patients, 7 too early for evaluation. Toxicity consisted of predominate Grade 1/2, that included constipation, nausea, vomiting, and fatigue. One Grade 3 toxicity consisting of nausea. 1 patient expired secondary to a CNS bleed while on therapeutic doses of coumadin. Conclusions: CC-4047 shows promising acitivity in patients with HRPCa, with an acceptable tolerability. We have increased the dose to 2 mg per day and will further evaluate patients with HRPCa. Additional results will be updated at the meeting. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Celgene
The health effects of heptachlor
Authors: H. Frumkin
Journal: JAMA (1987)

<h3>In Reply.—</h3> We appreciate the comments of Drs Saunders and Frear. Dr Saunders seems to be interested in the composition of the questions regarding patient attitudes that we used in our study. All patients in study 2 were given a questionnaire at the completion of the study and were requested to answer yes or no to the following questions: (1) "Did the information sheet change your attitude about taking the medicine?" (2) "Do you think this medicine is less safe after learning about it?" (3) "Do you think patients should know more about their medicine?" and (4) "Over the past month, have you had any problems which you think are caused by the medicine?" The questionnaire was part of a randomized controlled study, so all patients in study 2 received the questionnaire whether or not they received the drug information sheet. As we noted in our article, the reported attitude
<i>Announcement: </i>Community Preventive Services Task Force Recommendation for Family-Based Interventions to Increase Physical Activity
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

The Community Preventive Services Task Force recently posted new information on its website: "Physical Activity: Family-Based Interventions." This information is available at https://www.thecommunityguide.org/findings/physical-activity-family-based-interventions.
Canadian Journal of Surgery, Toronto
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal